Regulatory actions for Aug. 6, 2020
Read the full article on BIOWORLD.COM
Entries by Organicell
Landmark Hospitals Compassionate Use Study for Critical COVID-19 Patients Evidences Potential for Allogenic Biologic Product
Read the full article here: https://www.trialsitenews.com/landmark-hospitals-compassionate-use-study-for-critical-covid-19-patients-evidences-potential-for-allogenic-biologic-product/
Journal of Extracellular Vesicles
Read the full article on TANDFONLINE.COM
Going Acellular: An Interview with Organicell
Read the full article on REGENMEDNET.COMV
Organicell Reports Positive Results from Compassionate Use of Organicell Flow in Severely Ill COVID-19 Patients
MIAMI, May 27, 2020 (GLOBE NEWSWIRE) — Organicell Regenerative Medicine, Inc. (OTCBB:BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today a health update for two critically ill COVID-19 patients who were treated at Landmark Hospital in Athens, GA with the Company’s Organicell Flow product. These patients were treated under the […]
Investors Search for Promising Covid Cures
Read the full article by legendary Wall Street writer Gene Marcial on Forbes.com.
MicroRNA Sequencing of Amniotic Fluid Derived Exosome Cargo Reveals a Therapeutic Potential for the Treatment of Osteoarthritis
M.A.Bellio1 Z.Abdullah1 D.Steward1 A.Khan2 X.Xu2 G.C.Shapiro1 A.Mitrani1 M.Mitrani11Organicell Regenerative Medicine Inc., Miami, Florida, United States2Assureimmune, LLC., Miami, Florida, United States Background & Aim Exosomes are being tested for their use as therapeutic agents in degenerative diseases such as Osteoarthritis (OA). However, the optimal source of exosomes is currently under investigation. Amniotic fluid (AF) is a […]
FDA Approves Two Emergency INDs to Administer Organicell Flow for COVID-19
FIRST PATIENTS TREATED WITH ORGANICELL FLOW THROUGH “EMERGENCY SINGLE PATIENT COMPASSIONATE USE” DESIGNATION Miami, FL (May 19, 2020) – Organicell Regenerative Medicine, Inc. (OTCBB:BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that on May 11, 2020, the U.S. Food and Drug Administration (FDA) authorized two Emergency Compassionate Use Investigational […]
Organicell Flow for Patients with COVID-19
Read the full article on CLINICALTRIALS.GOV.
Organicell Announces FDA Approval of IND Application for the Treatment of SARS Due to COVID-19
Miami, FL (May 5, 2020) — Organicell Regenerative Medicine, Inc. (OTCBB:BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its lead product, Organicell Flow, for patients diagnosed with moderate to severe acute respiratory […]
